FDA Accepts BLA for Spinal Muscular Atrophy Drug
December 3rd 2018Abeparvovec (Zolgensma) is a one-time infusion that replaces the defective or missing SMN1 gene with a functional copy that can create the SMN protein and prevent the loss of motor neurons in patients with spinal muscular atrophy.
Read More
Pharmacist Feature Friday: Providing Hope for Patients with Neurological Diseases
It’s our job to spend as much time as it takes to help patients feel comfortable with the medications they are taking.
Read More
FDA Grants Approval to First Biosimilar for Treatment of Non-Hodgkin's Lymphoma
November 29th 2018Officials with the FDA have approved rituximab-abbs (Truxima, Celltrion) as a biosimilar to Rituxan (Genentech), making it the first biosimilar for the treatment of adult patients with non-Hodgkin’s lymphoma.
Read More